Rebecca Byam

Rebecca Byam is a declared insider of HCW Biologics Inc. (finance chief), with filings sourced from SEC (Form 4). We count 25 filings; the first trade dates from 22 July 2021 and the latest from 22 May 2026.

No open-market sale appears; the market trades are 21 purchases worth €969k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant and 3 option exercises. 2026 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €31k. 14 out of 20 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 27 May 2026 with an open-market purchase (€17k) in HCW Biologics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.